A detailed history of Jane Street Group, LLC transactions in Liquidia Corp stock. As of the latest transaction made, Jane Street Group, LLC holds 120,427 shares of LQDA stock, worth $1.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
120,427
Previous 306,942 60.77%
Holding current value
$1.33 Million
Previous $4.53 Million 68.08%
% of portfolio
0.0%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$11.96 - $15.71 $2.23 Million - $2.93 Million
-186,515 Reduced 60.77%
120,427 $1.45 Million
Q1 2024

May 15, 2024

BUY
$11.35 - $16.73 $3.13 Million - $4.62 Million
276,026 Added 892.83%
306,942 $4.53 Million
Q4 2023

Feb 14, 2024

BUY
$5.77 - $12.19 $47,262 - $99,848
8,191 Added 36.04%
30,916 $371,000
Q3 2023

Nov 14, 2023

SELL
$6.27 - $8.15 $680,376 - $884,380
-108,513 Reduced 82.68%
22,725 $144,000
Q2 2023

Aug 14, 2023

BUY
$6.63 - $9.9 $683,175 - $1.02 Million
103,043 Added 365.47%
131,238 $1.03 Million
Q1 2023

May 15, 2023

SELL
$5.72 - $7.91 $379,567 - $524,891
-66,358 Reduced 70.18%
28,195 $194,000
Q4 2022

Feb 14, 2023

BUY
$4.68 - $6.54 $364,141 - $508,864
77,808 Added 464.66%
94,553 $602,000
Q3 2022

Nov 14, 2022

BUY
$3.73 - $8.39 $62,458 - $140,490
16,745 New
16,745 $91,000
Q2 2022

Aug 16, 2022

SELL
$3.37 - $7.55 $357,519 - $800,971
-106,089 Closed
0 $0
Q1 2022

May 17, 2022

BUY
$5.14 - $7.38 $545,297 - $782,936
106,089 New
106,089 $762,000
Q4 2020

Feb 17, 2021

SELL
$2.6 - $5.79 $53,760 - $119,719
-20,677 Closed
0 $0
Q3 2020

Nov 17, 2020

BUY
$4.34 - $8.28 $10,489 - $20,012
2,417 Added 13.24%
20,677 $102,000
Q2 2020

Aug 17, 2020

BUY
$4.86 - $11.44 $88,743 - $208,894
18,260 New
18,260 $154,000

Others Institutions Holding LQDA

About Liquidia Corp


  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $709M
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.